Envonalkib Versus Crizotinib in Treatment-Naive ALK-Positive Non-Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III Study
In brief
Envonalkib extended median progression-free survival to 30.4 months versus 12.0
In 264 previously untreated patients with ALK-positive lung cancer, envonalkib more than doubled median time without progression compared with crizotinib after about four years of follow-up. Genomic co-alterations identified patients with poorer outcomes, while resistance-related changes appeared in 14 of 52 analyzed after progression; overall survival data are still immature.
- Journal
- MedComm (Q1)
- Published
- 4 October 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Jie Huang, Yuanyuan Wang, Haishuang Sun, Jie Min, Nong Yang, Qitao Yu, et al.
- PMID
- 42830869
- DOI
- 10.1002/mco2.70998
Why clinicians should know about it
- Picked for Oncology and Radiation Oncology (paper of the day, 6 October 2026): Phase III RCT, robust PFS benefit
Abstract
This study reports efficacy and biomarker results from a multicenter, randomized, open-label Phase III study (NCT04009317). Treatment-naive anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients were centrally randomized 1:1 to envonalkib or crizotinib, stratified by brain metastases and chemotherapy lines. The primary endpoint was progression-free survival (PFS) assessed by independent review committee. This analysis updated investigator-assessed PFS. A total of 264 patients were randomized (envonalkib: 131, crizotinib: 133). Median follow-up was 46.5 and 46.8 months for envonalkib and crizotinib, respectively. Envonalkib significantly improved PFS over crizotinib (median PFS: 30.4 vs. 12.0 months, p < 0.0001; hazard ratio [HR] = 0.48, 95% CI: 0.35-0.65). Overall survival (OS) data remained immature. In the envonalkib group, circulating tumor DNA (ctDNA) analysis revealed poor prognosis for patients with co-mutations in p53 pathway genes (TP53, CDKN2A, MDM2, MDM4) or other concurrent oncogenic drivers (median PFS: 15.7 and 8.3 months). Among 52 patients with post-progression ctDNA data, putative resistance mechanisms were identified in 14 (26.9%), including secondary ALK mutations (n = 9) and/or bypass pathway activations (n = 9). Final follow-up confirms the robust benefit of envonalkib over crizotinib, supporting its role as a first-line option for ALK-positive NSCLC. Biomarker analyses validate the prognostic impact of genomic co-alterations and delineate resistance mechanisms.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.